Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease

Author:  ["Christopher D. Reiter","Xunde Wang","Jose E. Tanus-Santos","Neil Hogg","Richard O. Cannon III","Alan N. Schechter","Mark T. Gladwin"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Although the deleterious vasoconstrictive effects of cell-free, hemoglobin-based blood substitutes have been appreciated, the systemic effects of chronic hemolysis on nitric oxide bioavailability have not been considered or quantified. Central to this investigation is the understanding that nitric oxide reacts at least 1,000 times more rapidly with free hemoglobin solutions than with erythrocytes. We hypothesized that decompartmentalization of hemoglobin into plasma would divert nitric oxide from homeostatic vascular function. We demonstrate here that plasma from patients with sickle-cell disease contains cell-free ferrous hemoglobin, which stoichiometrically consumes micromolar quantities of nitric oxide and abrogates forearm blood flow responses to nitric oxide donor infusions. Therapies that inactivate plasma hemoglobin by oxidation or nitric oxide ligation restore nitric oxide bioavailability. Decompartmentalization of hemoglobin and subsequent dioxygenation of nitric oxide may explain the vascular complications shared by acute and chronic hemolytic disorders.

Cite this article

Reiter, C., Wang, X., Tanus-Santos, J. et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8, 1383–1389 (2002). https://doi.org/10.1038/nm1202-799

View full text

>> Full Text:   Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease

Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease

Induction of angiogenesis in a mouse model using engineered transcription factors